KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Finished Goods (2016 - 2025)

Astrazeneca has reported Finished Goods over the past 11 years, most recently at $1.9 billion for Q4 2025.

  • Quarterly results put Finished Goods at $1.9 billion for Q4 2025, up 26.76% from a year ago — trailing twelve months through Dec 2025 was $1.9 billion (up 26.76% YoY), and the annual figure for FY2025 was $1.9 billion, up 26.76%.
  • Finished Goods for Q4 2025 was $1.9 billion at Astrazeneca, up from $1.5 billion in the prior quarter.
  • Over the last five years, Finished Goods for AZN hit a ceiling of $2.0 billion in Q4 2021 and a floor of $1.4 billion in Q4 2022.
  • Median Finished Goods over the past 5 years was $1.6 billion (2023), compared with a mean of $1.7 billion.
  • Biggest five-year swings in Finished Goods: skyrocketed 40.6% in 2021 and later dropped 29.77% in 2022.
  • Astrazeneca's Finished Goods stood at $2.0 billion in 2021, then decreased by 29.77% to $1.4 billion in 2022, then increased by 10.97% to $1.6 billion in 2023, then dropped by 3.25% to $1.5 billion in 2024, then grew by 26.76% to $1.9 billion in 2025.
  • The last three reported values for Finished Goods were $1.9 billion (Q4 2025), $1.5 billion (Q4 2024), and $1.6 billion (Q4 2023) per Business Quant data.